Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Ausun Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:603229'
s EV-to-FCF Range Over the Past 10 Years
Min: -1993.49 Med: 36.16 Max: 1491.22
Current: -218.79
During the past 13 years, the highest EV-to-FCF of Zhejiang Ausun Pharmaceutical Co was 1491.22. The lowest was -1993.49. And the median was 36.16.
SHSE:603229's EV-to-FCF is ranked worse than 100% of 317
companies
in the Biotechnology industry
Industry Median: 15.24
vs SHSE:603229: -218.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Ausun Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Ausun Pharmaceutical Co's share price for today is ¥7.98.
Zhejiang Ausun Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Ausun Pharmaceutical Co EV-to-FCF Related Terms
Zhejiang Ausun Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603229 vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's EV-to-FCF falls into.
Zhejiang Ausun Pharmaceutical Co's current Enterprise Value is ¥5,900.4 Mil.
Zhejiang Ausun Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-27.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a EV-to-FCF of -215.75 as of Sep. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #999999 out of 317 companies in the Biotechnology industry.
Is Zhejiang Ausun Pharmaceutical Co's EV-to-FCF too high?
Zhejiang Ausun Pharmaceutical Co's current EV-to-FCF is -215.75. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #999999 out of 317 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #999999 out of 317 companies for EV-to-FCF. This places Zhejiang Ausun Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 15.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.24, based on 317 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Ausun Pharmaceutical Co's current EV-to-FCF is -215.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥9.43, compared to a current price of ¥7.98 — trading 15.4% below its estimated fair value. The current EV-to-FCF is -215.75. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current EV-to-FCF is -215.75 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.98 is trading 15.4% below its estimated GF Value™ of ¥9.43.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
EV-to-FCF: -215.75
GF Value™: ¥9.43 vs. price of ¥7.98 (15.4% below fair value)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
82GF Score
Get the complete analysis for SHSE:603229
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
